Cannabis Therapy Corp. (OTC: CTCO), a development stage company aiming to become a leader in the research, development, and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements, recently announced it is starting exploratory laboratory research to develop cannabinoid-based products with applications for the treatment of inflammation and auto-immune diseases.

“We are very excited to start this line of research and product development,” said Cannabis Therapy Corp. President and CEO Soren Mogelsvang. “Inflammation plays a significant role in a multitude of diseases and hemp based, anti-inflammatory products could potentially have widespread application in indications such as inflammatory bowel disease, arthritis, and psoriasis.”

The company plans on establishing a series of inflammation assays and models with the goal of developing a hemp-extract profiling platform. With the platform in place, the team will be able to identify and characterize hemp strains that are ideal for development of specific anti-inflammatory products. These efforts could kick start product commercialization by rapidly identifying specific promising compounds.

Last month, the company announced that its initial crop of hemp cultivars was well underway with plants exhibiting normal healthy growth characteristics and a height of approximately 16 inches at the time. The company plans to use hemp plants as a source of nutraceutical ingredients, since hemp’s legality has already been well established in court cases like HIA v. DIA back in 2004.

“Working with a fourth generation Colorado farmer has provided us a real advantage towards reestablishing the domestic hemp industry over many other growers who are exploiting the regulatory environment and attempting outdoor cultivation in the region for the first time,” added Mr. Mogelsvang. “We believe this initial acreage will adequately deliver a regional source of natural [hemp].”

The company’s unique combination of growing its own low-THC hemp and using translational biomedical assays for product development could enable it to rapidly bring its unique, laboratory tested nutraceuticals to market.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: